Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
C-MER Medical HoldingsHKSE:03309 -0.58%83 EBITDA Margin % is 9.11% as of Dec. 2025, which is 52% below its 10-year median of 19.17. GuruFocus rates HKSE:03309 with a GF Score™ of 83/100 and a GF Value™ of HK$2.77 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 670 Healthcare Providers & Services companies, C-MER Medical Holdings ranks worse than 54.03% on this metric.
C-MER Medical Holdings (HKSE:03309) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
C-MER Medical Holdings EBITDA Margin % Related Terms
C-MER Medical Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for C-MER Medical Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:03309 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, C-MER Medical Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C-MER Medical Holdings EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, C-MER Medical Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where C-MER Medical Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C-MER Medical Holdings (HKSE:03309) has a EBITDA Margin % of 9.11% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on C-MER Medical Holdings and its competitors. This is 52% below median its historical median of 19.17. Over the past decade, C-MER Medical Holdings' EBITDA Margin % has ranged from 9.24 to 28.93. According to the industry distribution chart, C-MER Medical Holdings ranks #362 out of 670 companies in the Healthcare Providers & Services industry, placing it in the top 54%.
Is C-MER Medical Holdings' EBITDA Margin % too high?
C-MER Medical Holdings' current EBITDA Margin % of 9.11% is 52% below median its 10-year median of 19.17. Over the past 10 years, this metric has ranged from a low of 9.24 to a high of 28.93. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. C-MER Medical Holdings' value of 9.11% is 11% below this industry median. Based on the distribution chart, C-MER Medical Holdings ranks #362 out of 670 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, C-MER Medical Holdings has a GF Score™ of 83/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does C-MER Medical Holdings' EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, C-MER Medical Holdings ranks #362 out of 670 companies for EBITDA Margin %. This places C-MER Medical Holdings in the lower half of its industry. The industry median EBITDA Margin % is 10.24. C-MER Medical Holdings' value of 9.11% is 11% below this benchmark. Historically, C-MER Medical Holdings' own EBITDA Margin % has ranged from 9.24 to 28.93 over the past decade. While the company's 10-year median is 19.17 vs. the industry median of 10.24, C-MER Medical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 670 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C-MER Medical Holdings's current EBITDA Margin % of 9.11% is 11% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on C-MER Medical Holdings and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C-MER Medical Holdings's current EBITDA Margin % is 9.11%, which is 52% below median its own 10-year median of 19.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-MER Medical Holdings stock overvalued right now?
Based on GuruFocus' analysis, C-MER Medical Holdings (HKSE:03309) is currently considered Possible Value Trap. The stock's GF Value™ is HK$2.77, compared to a current price of HK$0.86 — trading 69.1% below its estimated fair value. The current EBITDA Margin % is 9.11%, which is 52% below median its 10-year median of 19.17 and 11% below the Healthcare Providers & Services industry median of 10.24. C-MER Medical Holdings' overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For C-MER Medical Holdings (HKSE:03309), the current EBITDA Margin % is 9.11% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C-MER Medical Holdings (HKSE:03309) Overvalued in 2026?
Based on GuruFocus' analysis, C-MER Medical Holdings stock appears to be undervalued.
The current stock price of HK$0.86 is trading 69.1% below its estimated GF Value™ of HK$2.77.
GuruFocus considers C-MER Medical Holdings to be Possible Value Trap.
Key valuation signals for HKSE:03309:
EBITDA Margin %: 9.11% (52% below median its 10-year median of 19.17)
GF Value™: HK$2.77 vs. price of HK$0.86 (69.1% below fair value)
Industry Position: 11% below the Healthcare Providers & Services median (#362 of 670)
No single metric tells the full story. See the HKSE:03309 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C-MER Medical Holdings Ltd is a ophthalmic medical chain group in Hong Kong and the Greater Bay Area. With ophthalmology as its core, it has gradually expanded its business scope to different specialist services. The company through its subsidiaries are principally engaged in the provision of ophthalmic, dental and other medical services, sales of vision aid products and sales of medical consumables in Hong Kong and Mainland China. Geographically, the company generates revenue from Mailand China, and Hong Kong, with the majority of revenue generated from Mainland China.
83GF Score
Get the complete analysis for HKSE:03309
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03309 has been successfully added to your 
